$ACRV News

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Acrivon Therapeutics Q4 EPS $(0.49) Beats $(0.57) Estimate

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Acrivon Therapeutics To Reveal Pre-Clinical AP3 Data At The 2026 AACR Annual Meeting

Acrivon Therapeutics, Inc. (ACRV) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow

Acrivon Therapeutics, Inc. (ACRV) Presents at ESGO 27th Annual Congress 2026 - Slideshow

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer

Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory

Acrivon Therapeutics Expands Internally Operated Clinical Laboratory Improvement Amendment (CLIA) Certified Laboratory

Acrivon Therapeutics Expands Internally Operated Clinical Laboratory Improvement Amendment (CLIA) Certified Laboratory

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress